Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study

Pauliat E., Onken M., Weber-Schoendorfer C., Rousson V., Addor M., Baud D., ...Daha Fazla

MULTIPLE SCLEROSIS JOURNAL, cilt.27, ss.475-478, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1177/1352458520929628
  • Dergi Adı: MULTIPLE SCLEROSIS JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.475-478
  • Anahtar Kelimeler: Fingolimod, interferon, multiple sclerosis, pregnancy, birth defect, cohort study, MATERNAL EXPOSURE
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-beta-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-beta group (odds ratio, 2.2; 95% confidence interval, 0.2-24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-beta-exposed pregnancies was 0.6 (95% confidence interval, 0.2-1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.